Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHASE II STUDY OF MINI-CHOP PLUS OFATUMUMAB (O) IN NON PREVIOULSY TREATED PATIENTS AGED OVER 80 YEARS WITH CD 20+ DIFFUSE LARGE B-CELL LYMPHOMA

Trial Profile

PHASE II STUDY OF MINI-CHOP PLUS OFATUMUMAB (O) IN NON PREVIOULSY TREATED PATIENTS AGED OVER 80 YEARS WITH CD 20+ DIFFUSE LARGE B-CELL LYMPHOMA

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ofatumumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms LNH09-7B
  • Most Recent Events

    • 12 Dec 2023 Results comparing Synthetic control arms (SCA) with real-world (RW) data treated by anti-CD20+miniCHOP in LNH03-7B and LNH09-7B along with SENIOR trial, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 06 Dec 2016 Results of pooled analysis assessing CNS relapse, risk factors and specific survival in very elderly DLBCL patients using patient data from this and NCT01087424 trial, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 07 Apr 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top